|
Press Releases |
|
 |
|
Monday, June 2, 2025 |
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1) more info >> |
|
エーザイ、国内 OTC 医薬品初となるプロトンポンプ阻害薬「パリエット(R) S」新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、本日、胃酸逆流などによるつらい胸やけ・胃痛に優れた効果を発揮する「パリエット®S(要指導医薬品)」を全国の薬局、ドラッグストアにて新発売します。 more info >> |
|
Thursday, May 29, 2025 |
|
エーザイ、米国におけるレンバチニブに関する特許侵害訴訟の勝訴について |
当社は、当社創製の経口チロシンキナーゼ阻害剤「レンビマ®」(一般名:レンバチニブメシル酸塩)に関する特許(米国特許第 11,186,547 号、以下、ʼ547 特許)侵害を理由として、本剤に関する後発医薬品の簡略新薬承認申請(ANDA)を行った後発医薬品メーカー(Shilpa Medicare Limited(以下、Shilpa))に対し、2019 年 11 月に米国ニュージャージー州連邦地方裁判所に特許侵害訴訟を提起していましたが、2025 年 5 月 28 日に、当社勝訴の判決を得ましたので、お知らせします。 more info >> |
|
Wednesday, May 28, 2025 |
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
Wednesday, May 21, 2025 |
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、2025 年 5 月 30 日から6 月3日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会(American Society of Clinical Oncology:ASCO)年次総会」(2025 ASCO Annual Meeting)において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
Friday, May 16, 2025 |
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
Wednesday, April 30, 2025 |
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
Friday, April 18, 2025 |
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
Wednesday, April 16, 2025 |
|
エーザイとバイオジェン、「レケンビ」(レカネマブ)が欧州連合(EU)において早期アルツハイマー病の進行を抑制する初めての治療剤として承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:Christopher A.Viehbacher、以下 バイオジェン)は、このたび、抗アミロイドベータ(Aβ)モノクローナル抗体「レケンビ®」(一般名:レカネマブ)について、欧州委員会(European Commission)より、欧州連合(EU)における販売承認を取得したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Legacy and Lifestyle: U.S. Polo Assn. Hosts Iconic Party at Pitti Uomo 108 in Florence, Italy
Jun 19, 2025 22:30 HKT/SGT
|
|
|
New method to blend functions for soft electronics
Jun 19, 2025 21:10 HKT/SGT
|
|
|
中國品質火鍋第一品牌 巴奴毛肚火鍋終於遞交港股招股書!
Jun 19, 2025 16:15 HKT/SGT
|
|
|
中国品质火锅第一品牌 巴奴毛肚火锅终于递交港股招股书!
Jun 19, 2025 16:11 HKT/SGT
|
|
|
How Containers Supercharge AI Development Projects
Jun 19, 2025 15:56 HKT/SGT
|
|
|
实践社会责任守护生命价值 上海福寿园连续三届蝉联「全国文明单位」荣誉称号背后的故事
Jun 19, 2025 13:14 HKT/SGT
|
|
|
實踐社會責任守護生命價值 上海福壽園連續三屆蟬聯「全國文明單位」榮譽稱號背後的故事
Jun 19, 2025 12:05 HKT/SGT
|
|
|
Sharp Launches A2 Size ePoster Color Electronic Paper Display
Jun 19, 2025 12:08 JST
|
|
|
CleverTap Launches 'Promos' - The Industry-First All-In-One Rewards Management Platform
Jun 19, 2025 10:19 HKT/SGT
|
|
|
富士通、AIアバターがプレゼンテーションや質疑応答対応を行う「Fujitsu AI Auto Presentation」を開発
Jun 19, 2025 10:10: JST
|
|
|
Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations
Jun 19, 2025 10:25 JST
|
|
|
Canstar Strengthens Technical Advisory Board with the Appointment of Geologist and VMS Mineralization Expert, Dr. Stephen J. Piercey, P.Geo., FGC
Jun 19, 2025 09:15 HKT/SGT
|
|
|
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 9:30 JST
|
|
|
U.S. Polo Assn. 於佛羅倫斯聖母瑪利亞新教堂盛大慶祝品牌創立 135 週年,並在 Pitti Uomo 108 發表 2026 年春夏系列
Jun 19, 2025 07:00 HKT/SGT
|
|
|
容器如何加速人工智慧開發專案
Jun 19, 2025 07:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|